| Date Filed | Type | Description |
| 11/22/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 11/19/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/12/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 11/12/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 11/12/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/12/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 11/12/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 11/12/2019 |
8-K
| Quarterly results |
| 11/12/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/12/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 11/01/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/01/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/29/2019 |
GN
| SHAREHOLDER ALERT: WeissLaw LLP Reminds DOVA, TRCB, EEI, and UCFC Shareholders About Its Ongoing Investigations |
| 10/11/2019 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 10/11/2019 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/03/2019 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 10/03/2019 |
8-K
| Quarterly results |
| 10/02/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dova Pharmaceuticals, Inc. to Swedish Orphan Biovitrum AB is Fair to Shareholders |
| 10/01/2019 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 10/01/2019 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 09/30/2019 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 09/30/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/30/2019 |
GN
| Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi) |
| 09/25/2019 |
GN
| Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference |
| 09/03/2019 |
GN
| Dova Pharmaceuticals to Present at Upcoming Investor Conferences |
| 08/06/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 08/06/2019 |
8-K
| Quarterly results |
| 07/30/2019 |
GN
| Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019 |
| 07/19/2019 |
GN
| Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP) |
| 06/27/2019 |
8-K
| Quarterly results |
| 06/27/2019 |
GN
| Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP) |
| 06/24/2019 |
GN
| Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress |
| 05/20/2019 |
GN
| Dova Pharmaceuticals to Present at the UBS Global Healthcare Conference |
| 05/07/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
|